Coverting unresectable to resectable: Data still limited

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 12
Volume 17
Issue 12

There is growing agreement with Dr. Falcone-based on limited data-that response rates appear to be increased with FOLFOX plus cetuximab, as compared with FOLFOX alone, for KRAS wild-type patients only, according to Jordan Berlin, MD, associate professor of medicine and clinical director of GI oncology at Vanderbilt University in Nashville.

There is growing agreement with Dr. Falcone-based on limited data-that response rates appear to be increased with FOLFOX plus cetuximab, as compared with FOLFOX alone, for KRAS wild-type patients only, according to Jordan Berlin, MD, associate professor of medicine and clinical director of GI oncology at Vanderbilt University in Nashville.

“We do not have data, on the other hand, that definitively show higher response rates with chemotherapy plus bevacizumab,” Dr. Berlin pointed out. “Therefore, if the goal is to convert patients from unresectable to resectable status, the available data suggest that cetuximab accomplishes this. We must acknowledge, however, that the data are still very limited and resectability has not been the primary endpoint of any study.”

Dr. Berlin also noted that cetuximab has not been associated with wound healing problems, which is a concern with bevacizumab, though recent findings have been more reassuring.

Since current data have been “extracted” from trials and are not the result of randomization, “to say that one agent is definitely better than the other is standing on shaky ground.”

 

The main article can be found here:
New presurgical strategies render colon mets resectable

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content